ARS Pharmaceuticals, Inc.
SPRY
$8.54
$0.526.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1,165.02% | -2,241.76% | -63.00% | -7.08% | 68.51% |
| Total Depreciation and Amortization | 326.44% | 1,630.38% | 1,479.03% | 882.26% | 443.75% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 141.54% | 161.88% | 230.58% | 215.76% | 182.78% |
| Change in Net Operating Assets | 93.17% | -1,005.58% | -1,102.23% | -410.73% | -100.94% |
| Cash from Operations | -754.67% | -1,361.19% | -86.16% | -19.57% | 61.75% |
| Capital Expenditure | 56.57% | 39.79% | -277.06% | -700.00% | -778.46% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 182.03% | 154.11% | -413.08% | 83.87% | -526.89% |
| Cash from Investing | 180.99% | 153.50% | -418.49% | 82.50% | -532.25% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 44.07% | 88.36% | 65.27% | 59.68% | -40.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -96.03% | -96.17% | -- | -- | -- |
| Cash from Financing | 42.77% | 44.47% | 5,203.62% | 2,025.76% | 1,148.13% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.71% | 52.86% | 195.33% | 118.10% | 49.33% |